BIOMAT Database Logo BIOMAT Database Logo

Debrisoquine oxidation phenotype in psychiatric patients. 1989

J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, Spain.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Debrisoquine oxidation phenotype during neuroleptic monotherapy.
January 1991, European journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
January 1990, British journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions.
November 1992, Acta psychiatrica Scandinavica,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
October 1990, British journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Debrisoquine hydroxylation phenotype in SLE patients.
January 1989, Scandinavian journal of rheumatology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
January 1987, European journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
January 1991, European journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Predicting debrisoquine phenotype.
February 1991, Lancet (London, England),
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
January 1990, European journal of clinical pharmacology,
J Benítez, and B Piñas, and M A García, and C Martínez, and A Llerena, and J Cobaleda
Determination of debrisoquine oxidation phenotype in healthy volunteers during phase I trials.
January 1996, Therapie,
Copied contents to your clipboard!